IPSEN (OTCMKTS:IPSEY) Shares Gap Down – What’s Next?

IPSEN (OTCMKTS:IPSEY) gapped down prior to trading on Thursday . The stock had previously closed at $46.2280, but opened at $44.82. IPSEN shares last traded at $44.82, with a volume of 125 shares trading hands.

Analysts Set New Price Targets

IPSEY has been the subject of several recent research reports. Zacks Research upgraded IPSEN to a “hold” rating in a research note on Friday, May 29th. HC Wainwright reaffirmed a “buy” rating on shares of IPSEN in a report on Tuesday, June 30th. Barclays downgraded shares of IPSEN from an “equal weight” rating to an “underweight” rating in a research note on Tuesday, September 8th. Finally, Jefferies Financial Group cut shares of IPSEN from a “hold” rating to a “moderate sell” rating in a report on Sunday, August 2nd. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Reduce”.

IPSEN Stock Performance

The business has a 50 day moving average price of $46.47 and a 200-day moving average price of $46.74.

About IPSEN

Ipsen SA is a France-based biopharmaceutical company that develops and commercializes specialty medicines for serious diseases. Its primary focus areas are oncology, rare diseases and neuroscience, with research and development activities aimed at addressing conditions that often have limited treatment options.

The company’s portfolio includes medicines such as Somatuline (lanreotide) for certain neuroendocrine tumors and endocrine disorders, Dysport (abobotulinumtoxinA) for selected neurological and muscular conditions, and oncology treatments including Cabometyx and Onivyde.